Cleerly raises $192M for AI-based software to spot atherosclerosis

Cleerly announced today that it closed an oversubscribed Series C financing round with proceeds of $192 million.

New York-based Cleerly has now raised $248 million in total, including its Series B round in 2021.

The company develops an AI-enabled approach for evaluating coronary computed tomography (CT) angiograms, allowing physicians to more easily identify, characterize and qualify atherosclerosis (plaque) build-up in the walls of the heart arteries. The information provided by Cleerly’s technology promotes a more accurate understanding of a patient’s risk of heart attack, shifting away from the way heart disease has previously been assessed through indirect surrogate markers of disease.

“At Cleerly, we are passionate about our mission to create a new standard of care for heart disease,” Cleerly CEO and founder Dr. James Min said in a news release. “We are grateful for this round of financing that will further enable our work and believe it…

Read more
  • 0

Cleerly launches digital heart attack prevention software following $43M Series B

Cleerly today said it has launched its digital care software for heart attack prevention following a $43 million Series B funding round.

New York-based Cleerly’s digital care technology is a non-invasive coronary computed tomography angiography that performs coronary artery phenotyping through artificial intelligence. According to the company, it uses millions of annotated lab images to build more than two dozen algorithms that quantify and characterize the presence, extent, severity and type of coronary artery disease and other cardiovascular diseases.

“Advanced imaging has been key to diagnosing and preventing the most common causes of cancer for years, but we’re not using it yet to prevent the most common cause of death. We use 3D mammograms, colonoscopies and lung CT scans to find and prevent breast, colon and lung cancer, but we haven’t had similar capabilities for the world’s number one killer – heart disease,” CEO James Min said in a news release. …

Read more
  • 0